Dr. Seidah obtained his BSc in 1969 from Cairo University in Egypt, and his PhD in 1973 from Georgetown University, USA. In 1974, he started studying the processing of precursor proteins at the Montreal Clinical Research Institute (IRCM), and in 1976 he co-discovered the β-endorphin and largely contributed to the biochemical characterization of the proopiomelanocortin (POMC, the β-endorphin precursor) and pro-Atrial Natriuretic factor. Since 1983, Dr Seidah is the director of Laboratory of Biochemical Neuroendocrinology.
Dr. Seidah discovered and cloned seven (PC1, PC2, Furin, PC4, PC5, PACE4, PC7, SKI-1 and PCSK9) of the nine known secretory serine proteases belonging to the proprotein convertases family. During this period, he also greatly contributed to demonstrating that proteolysis by the proprotein convertases is a widely used mechanism that also affects “non-neuropeptide” proteins such as growth factors, α-integrins, receptors, enzymes, membrane-bound transcription factors, and bacterial and viral proteins. In 2003, he identified PCSK9 and showed that point mutations in the PCSK9 gene cause dominant familial hypercholesterolemia, since PCSK9 gain-of-function mutations were linked to the ability of PCSK9 to enhance the degradation of cell surface receptors, such as the low-density lipoprotein receptor (LDLR). Dr Seidah has since worked on the elucidation of the functions and mechanisms of action of PCSK9 both in cells and in vivo, and is developing specific PCSK9 inhibitors.